Safety
What's worth tracking on therapy, what FDA adverse event reports do and don't tell you, and why the 'research peptide' market is a meaningfully different risk profile from prescription GLP-1s.
5 articles
Safety
GLP-1 drugs and muscle: what does the science actually say?
A 2026 Cell Reports Medicine study found GLP-1 medicines mainly reduce fat, not muscle. Here's what the latest science shows — and what you and your clinician can do about it.
4 min · Updated 2026-05-27
Safety
What FDA's adverse event reports on compounded GLP-1s actually tell patients
The FDA reports 605 adverse events tied to compounded semaglutide. Here's what those numbers mean — and which risks patients should actually watch for.
6 min · Updated 2026-05-27
Safety
'Research peptide' vs prescription GLP-1: why the distinction matters
Vials sold online as 'research only' are not the same product as an FDA-approved or pharmacy-compounded GLP-1. Here is why that gap matters.
6 min · Updated 2026-05-27
Safety
GLP-1 side effects: what to track
A practical list of side effects commonly reported with GLP-1 therapy, what they often mean, and what to log so your clinician can act on patterns.
11 min · Updated 2026-05-27
Safety
Unregulated peptides and real harm: what Australia's hospitalization surge shows
Australia's drug regulator issued a formal safety alert in April 2026 after hospitalizations from unregulated injectable peptides. Here's what consumers should understand.
5 min · Updated 2026-05-27